Illinois State University

ISU ReD: Research and eData
Theses and Dissertations
6-28-2020

Adsorption Behavior Of Chemically/Charged Modified Antibodies
On Gold Nanoparticles
Samuel Okyem
Illinois State University, okyemsamuel@gmail.com

Follow this and additional works at: https://ir.library.illinoisstate.edu/etd
Part of the Analytical Chemistry Commons, and the Biochemistry Commons

Recommended Citation
Okyem, Samuel, "Adsorption Behavior Of Chemically/Charged Modified Antibodies On Gold
Nanoparticles" (2020). Theses and Dissertations. 1303.
https://ir.library.illinoisstate.edu/etd/1303

This Thesis is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of ISU ReD: Research and eData. For more
information, please contact ISUReD@ilstu.edu.

ADSORPTION BEHAVIOR OF CHEMICALLY/CHARGED MODIFIED ANTIBODIES ON
GOLD NANOPARTICLES

SAMUEL OKYEM
82 Pages
Gold nanoparticles (AuNPs) have been exploited in the various domains of science such
as drug delivery, bio-sensing, immunoassays and environmental sensors, due to their optical
properties and intriguing surface chemistry. Different scientific procedures have been used to
effectively immobilize antibodies onto AuNPs. Although acceptable outcomes have been
achieved in the immobilization of antibodies onto AuNPs, the sensitivity of these immobilized
antibodies to target antigen or binding sites is limited due to improper orientation of the
antibodies. Also, the possibility of nanoparticle aggregation when exposed to proteins limits its
biomedical applicability.
There is some evidence that the surface charge of antibodies is responsible for controlling
the orientation upon adsorption to AuNPs. Antibodies have ubiquitous lysine residues which are
protonated at physiological pH contributing to the total surface charge of the antibody. Chemical
modification of antibodies by reacting with acrylic acid N-hydroxysuccinimide ester and
thiosuccinimidylpropionate, acroleinate and thiopropionate lysine residues respectively,
consequently controlling the surface charge of the antibodies and potentially impacting the
orientation upon adsorption to AuNPs.
In this proceeding, novel analytical techniques are utilized to directionally adsorb charge
modified antibodies onto citrate capped AuNPs to increase the amount of exposed active site.

Dynamic light scattering, fluorescence, nanoparticle tracking analysis and other analytical
strategies have been used to study the adsorption dynamics, kinetics, and orientation of these
charged modified antibodies on AuNPs. These fundamental investigations to elucidate the
mechanism of protein-AuNP adsorption will lead to optimized bioconjugates that are necessary
to realize the full potential of AuNP-enabled bio-nanotechnologies.
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CHAPTER I: INTRODUCTION
Immunoassay and Gold nanoparticle (AuNP)
Disease diagnosis is a critical area in medicine since it remains the first fundamental
process of medical care. Diagnostic tools with high sensitivity and selectivity are in stark
demand as they allow for early and effective diagnosis which decreases disease threats and
mitigates the excessive use of drugs.
Immunoassays remain one of the most effective techniques for diagnosing infectious
diseases, cancer, autoimmune disease, etc. Recent advancement in enzyme, fluorescence,
chemiluminescence, and radio immunoassay have contributed to early diagnoses of disease and
lower detection limits.4 However, these techniques are labor intensive and may employ the use of
hazardous chemicals, or require specialized facilities and highly skilled personnel. It is,
therefore, necessary to explore alternative cost effective, highly sensitive and time efficient
analytical techniques that require no specific training for use, e.g. pregnancy test strips, for
various disease diagnosis. Gold Nanoparticles (AuNPs) having outstanding optical, chemical,
electrical and catalytic properties have been exploited in drug delivery, therapeutics, bioimaging,
biosensors and in immunoassays.5,6 Recently, several advancements have been made in AuNP
enabled immunoassays; nonetheless the applicability of these techniques are still limited due to
their low sensitivity. This lower sensitivity is attributed to random orientation of antibody or
antigen on the AuNP surface which decreases the number of accessible binding sites. In this
research we seek to develop a technique leading to the formation of highly stabilized, functional,
and selective antibody-AuNP conjugates with high sensitivity to promote implementation of
AuNP-enabled immunoassays in disease diagnosis.

1

Time Evolution AuNP-Protein Corona
AuNPs for biomedical applications are mostly functionalized with aptamers, peptides,
proteins, glycans, peptidoglycans, etc.7,8 This biomolecule functionalized AuNP dictate the
function of the AuNP. Various techniques have been used in studying the time evolution of
protein corona on AuNP. Puntes and coworkers9 studied protein corona formation on AuNP in
cell culture medium supplemented with serum protein by measuring the Zeta potential and
conjugates size at different incubation times. From their findings, the Zeta potential of AuNP
which is a measure of the surface charge decreased exponentially with time, indicating the
formation of strongly stabilized conjugates with time. Also, they observed that at early
incubation time, several proteins with low affinity are loosely bound to the AuNP (soft corona),
which desorbs upon centrifugation. However, as time evolves, a highly stabilized hard corona of
protein is formed on AuNP. In this work, we intend to employ the use of zeta potential and size
measurement to probe the required time needed to irreversibly adsorb chemically modified and
unmodified antibodies onto AuNPs at different pHs.
Strategies for Synthesizing Antibody-AuNP Conjugates
Covalent Immobilization of Antibodies onto AuNP
Several methods exist for synthesizing AuNP-antibody conjugates. Among them is the
use of heterobifunctional linkers, which uses one of its arms mostly containing a thiol group to
bind selectively to the AuNP, and the other half reacts covalently with the antibody through 1ethyl-3-(3-dimethylaminopropyl)carbodiimide/dicyclohexyl carbodiimide (EDC/DCC) coupling
chemistry. In addition, covalent immobilization of antibodies on AuNP can be achieved by
adsorbing small molecules containing carboxylate functional on to AuNP followed by coupling
of antibodies through NHS (N-hydroxy succinimide), EDC, and DCC chemistry to form amide
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bonds. Several other methods have been developed for covalent immobilization, however these
immobilization techniques require more antibodies, and also results in fewer antibodies being
immobilized onto AuNP.10
Direct Antibody Immobilization on AuNP
Antibody-AuNP conjugates can also be synthesized by directly incubating antibodies
with AuNP.11,12 Recent advancement in protein-AuNP chemistry reports electrostatic interaction
between negatively charged citrate capped nanoparticles13 and proteins as the primary driving
force facilitating the adsorption of proteins onto AuNP. Subsequently, the interaction between
free sulfhydryl and amino groups and the AuNP have been reported as secondary interactions
leading to the formation of a hard corona of protein on AuNP.9 Highly stable antibody-AuNP
conjugates have been synthesized using this procedure. However, this immobilization technique
is pH-dependent, thus stable conjugates can only be synthesized within a small pH range for each
specific antibody isotype or host type dictated by the isoelectric points exhibited by these
antibodies. In addition, direct immobilization of antibodies onto AuNPs results in random
orientation of antibody on AuNP surface which may cause paratope masking thereby reducing
the effectiveness of these conjugates in immunoassays.
Orientation Directed Antibody-AuNP Synthesis
Recently Richard M. Crooks and coworkers14 employed the use of a heterobifunctional
linker to control the orientation of antibodies on silver nanoparticles. The heterobifunctional
linker consisted of either a disulfide or free sulfhydryl at one end and a hydrazine at the other
half separated by a small alkyl group. In this work, the heterobifunctional linker is first
immobilized onto the AuNP, followed by antibody immobilization. Hydrazine on the
heterobifunctional linker preferentially reacts with the carbonyl of the polysaccharide at the Fc
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end of the antibody, whereas the sulfur containing functionality at the other arm of the linker
binds to the gold. This technique allowed the immobilization of antibodies onto AuNP and
AgNP through the Fc (fragment crystallizable) end rendering the Fab (fragment antigen binding)
end exposed for antigen binding. Protein A, which binds selectively to the Fc of antibodies, have
also been utilized for directionally oriented antibody-AuNP conjugates synthesis.15,16 Although a
high fraction of antibodies is oriented correctly for effective antigen binding only a small number
of antibodies are immobilized due to the bigger footprint of protein A on AuNP.
Protein/Antibody Gold Nanoparticle (AuNP) Interactions
Recent advancements in gold nanotechnology have rendered it very useful in
biomedicine.17 In order to maximize its usefulness in a biological environment it is pertinent to
understand the fundamental interaction of biomolecules with AuNP. Various analytical
techniques such as UV-visible spectrophotometry (UV-vis), dynamic light scattering (DLS),
nanoparticle tracking analysis (NTA), and florescence correlation spectroscopy (FSC) have been
employed to study the formation of protein corona on AuNP. However, a full, detailed, chemical
mechanism for the formation of protein corona on AuNP is yet to be unraveled. Electrostatic
interaction between negatively charged citrate capped AuNP and proteins have been reported as
the main fundamental force that drives the adsorption of proteins onto AuNP.13,18 Recent reviews
on protein AuNP interactions also suggests the occurrence of secondary interaction between
protein and AuNP,19,9,20 which leads to the formation of irreversibly bound protein (hard corona)
on AuNPs. These secondary interactions are reported to be driven primarily from free sulfhydryl
groups of proteins. Trout et al.21 deduced the interaction between DNA and AuNP to proceed
through the conjugated amines on the purine and pyrimidine bases after conducting a
computational adsorption study of methylamines on AuNP. Protein affinity for AuNP is also
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known to increase with increasing molecular weight as a result of increasing points of
interaction.22 These findings suggest that antibodies of molecular weight 150 kDa will have a
high binding affinity for AuNP. In this research, we seek to employ the use of UV-Vis, DLS and
NTA to understand the mechanism of adsorption of both unmodified and chemically modified
antibodies on AuNP, which will facilitate the development of a systematic procedure for
synthesizing highly stable and active conjugates for biomedical applications.
Protein Triggered Aggregation of Nanoparticles
It is well-established that proteins can adsorb onto AuNPs to result in a stable Ab-AuNP
conjugate, which resists aggregation under physiological conditions, e.g., high ionic strength. It
is less commonly reported, however, that protein can actually trigger the aggregation of
AuNPs.23,24 In the case of some proteins, the aggregation has been attributed to adsorption and
subsequent unfolding of the protein, which leads to destabilization and aggregation.25 Other
protein-triggered aggregation events have been attributed to a bridging mechanism.26 In this case,
proteins with positive charges on opposing sides of the macromolecule act as a bridge to
electrostatically crosslink two negatively charged AuNPs, e.g., citrate-capped AuNPs.
Accordingly, at lower pHs, antibodies will carry more positive charge and trigger AuNP
aggregation. This will limit the pH range over which the proposed antibody-AuNP binding
affinity experiments can be performed. Moreover, with respect to the long-term goal of the
project, certain antibodies will not form stable conjugates at lower pH values for use in
bioassays. To overcome this challenge, we propose to investigate the mechanism leading to
nanoparticle aggregation at lower pHs. We hypothesize that if the mechanism of protein induced
nanoparticle aggregation is through electrostatic bridging of antibodies then appropriate
modification will convert the protonated lysine, e.g., positive charge, to a neutral or negatively
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charged functional group to prevent protein-triggered aggregation via electrostatic bridging. This
work will provide a pathway to form stable antibody-AuNP conjugate at any pH which proves to
be optimal for antigen binding.
Thesis Objectives
Protein-AuNP conjugates have numerous promising biomedical applications, yet its
utilization is limited due to the possibility of AuNPs aggregating upon exposure to proteins.
Several interactions have been reported as the means through which protein induces aggregation
of nanoparticles. In this research, a systemically developed workflow for synthesizing proteinAuNP conjugates at different pH is being used to evaluate the impact of protein charge on
nanoparticle aggregation as well as the mechanism through which these aggregates are produced.
Preliminary studies in our lab indicate chemical modification of antibodies allows the
synthesis of antibody-AuNP conjugates at several pHs, however synthesis of some of these
conjugates require a long incubation time; understanding the underlying chemical interactions
resulting in long incubation as a result of chemical modification of antibody is therefore
essential. Here, we seek to employ various analytical techniques to investigate the effect of
chemical modification on conjugate stability, adsorption kinetics, adsorption dynamics, and
antigen-binding affinity.
Research Overview
The functionalization of AuNP surfaces with protein and other molecules defines its
functions and surface properties.18,27 Various analytical techniques have been employed to
immobilize proteins onto AuNPs for several applications,8,28 yet these immobilization techniques
are pH dependent and are mostly unique to a specific protein. Existing methods for synthesizing
antibody-AuNP conjugates mostly results in random orientation of antibodies on nanoparticle
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surface, which may cause masking of protein active sites, leading to reduced effectiveness of
these conjugates for biomedical applications. Although several attempts have been made to
understand the chemical interaction between protein and nanoparticle, no definite conclusions
have been reached.29–31 It is, therefore, important to search for alternative universal techniques
for synthesizing these conjugates to understand their chemistry that will improve the
applicability of antibody-AuNP conjugates in biomedicine.
To this end, this research is aimed at developing a strategy to synthesize highly active,
oriented, and stable antibody-AuNP conjugates for immunoassays. The primary objective of this
research is to investigate the adsorption dynamics and kinetics of unmodified and chemically
modified antibody onto AuNPs.
Antibodies ubiquitously contain lysine residues, which upon reacting with activated
esters leads to their acetylation. Chemical modification therefore modifies the charge on lysine
residues which results in a change in the total surface charge of the protein. We hypothesize that
antibody surface charge will direct its orientation on AuNP and contribute to the synthesis of
highly active, stable, and aggregation resistant antibody-AuNP conjugates. Previous findings
imply antibodies adsorbs irreversibly onto AuNPs,19 which removes the requirement of
specialized coupling techniques for antibody-AuNP conjugate formation; also, antibody surface
charge is known to dictate its orientation on AuNP which can be controlled with pH.32 Lastly,
chemical modification of antibodies alters the surface charge, defining its orientation on AuNP.
Our main aim is to develop a universal technique for the synthesis of highly active and stable
antibody-AuNP conjugates for AuNP-enabled immunoassays and biomedical applications.
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CHAPTER II: PROBING ANTIBODY- AuNP AGGREGATION MECHANISM
Introduction
Gold nanoparticles (AuNPs) have remarkable physicochemical properties and high
biocompatibility, and as a result they have been exploited in many emerging biomedical
applications,5,17 including drug delivery, photo-thermal therapy and disease diagnosis.17,28,33,34
The surface chemistry of AuNPs allows it to adsorb several biomolecules such as protein,
nucleic acids and lipids. However, the high surface energy of nanoparticles compared to the bulk
metal makes it kinetically and thermodynamically unstable. Although most biomolecules form
stable conjugates with AuNPs, an increase in surface energy due to biomolecule adsorption can
trigger nanoparticle aggregation. Bovine serum albumin, immunoglobulin G and some other
proteins have been shown to form stable conjugates with AuNPs at physiological pH,35 while
lysosomes and other proteins induce AuNP aggregation at physiological pH.23,36 To this point, it
becomes relevant to understand the mechanism by which these aggregations occurs, in other to
help improve the utility of AuNP-protein conjugates in a biological setting and avoid in vivo
detrimental effects. For some proteins, aggregation of AuNP is ascribed to the unfolding of
protein upon adsorption followed by destabilization .37 Also, other scientific evidence suggests
that proteins may trigger nanoparticle aggregation by an electrostatic bridging mechanism.38 For
this mechanism, exposed positive charges on proteins act as an electrostatic bridge to crosslink
negatively charged AuNPs, e.g., citrate capped AuNPs. Besides, the charge screening effect
caused by the displacement of negatively charged citrate by proteins on AuNPs reduces the
overall surface charge of the nanoparticles, decreasing the diffusion bilayer; the distance between
two AuNPs and electrostatic repulsion between nanoparticles.36 Diffusion bilayer depletion
brings two adjacent AuNPs into proximity where Van der Waals attractive forces predominate
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and may trigger the nanoparticle’s collapse. Protein surface charge is, therefore, an important
parameter to cause nanoparticle aggregation.
Research conducted by Katsuhiko and coworkers39 established the importance of
charged molecules on nanoparticle aggregation. In their work, they adsorbed various small
molecules that contain thiols, amines and carboxylates, e.g., urea, cysteine, and glutathione, onto
citrate capped AuNPs. Based on their findings, molecules with both amine and thiol functionality
seem to facilitate aggregation of the AuNPs. In contrast, thiols and carboxylate containing
molecules did not trigger the aggregation of nanoparticles. These results suggest either a possible
charge screening of the negatively charged citrate capped AuNPs or bridging of the two AuNPs
by amines upon displacement of citrate by the thiol-amine molecules.
The Driskell’s lab demonstrated the effectiveness of pH in controlling the orientation of
antibodies on AuNPs.40 The percentage of available antigen-binding sites of antibodies adsorbed
onto citrate capped AuNPs increased as a function of decreasing pH.40 However, we observed
aggregation of nanoparticles at pH below 7.5. This observation was attributed to an increase in
protein positive charge with decreasing pH, which tends to induce nanoparticle aggregation
through any of the mechanisms previously discussed. Protein surface charge is, therefore, an
important parameter to consider when synthesizing protein nanoparticle conjugates.
Herein, we have employed several analytical techniques to elucidate which of these
mechanisms drives the aggregation of antibody-AuNP conjugates. Knowledge of the aggregation
mechanism can help mitigate the effect of a lower pH on nanoparticle aggregation. This will
allow the synthesis of highly stable and oriented antibody-AuNP conjugates.
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Materials and Methods
Reagents
A 60 nm citrate capped AuNPs at a concentration of 2.6 × 10!" particles/mL was used in
all analyses. All antibody studies were performed using a mouse monoclonal anti-horseradish
peroxidase IgG (clone 2H11) obtained from My BioSource. Horseradish peroxidase (HRP), 2,2′azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) (1-Step ABTS) and potassium cyanide were
obtained from Thermo Scientific (Rockford, IL). Phosphate buffers were prepared using
anhydrous potassium phosphate dibasic and potassium phosphate monohydrate purchased from
Mallinckrodt Chemicals, Inc. (Paris, KY) and Fischer Scientific (Fair Lawn, NJ), respectively.
All experiments were performed using Nano pure deionized water from a Barnstead water
purification system (Thermo Scientific, Rockford, IL).
Antibody Characterization at Different pHs
A 2 mg/mL mouse anti-HRP antibody solution was prepared from a 4.4 mg/mL
commercial purchased stock solution by diluting in a 2 mM phosphate buffer (pH 7.5). This
solution was further diluted in 2 mM buffers of different pHs. Resuspension of antibodies were
carried out by diluting 50 µL of 2 mg/mL antibody at pH 7.5 to 500 µL with buffers of pH 5, 6,
7, 7.5, 8, and 9. The resulting anti-HRP solutions was concentrated using an Amicon filter
(MWC 100 KDa) by centrifugation at 14,000 g for 10 min to an approximate volume of 20 µL.
The concentrates were collected following results of the manufacturer’s recommendation. The
concentration of antibodies resuspended in buffers of different pH was determined by a
NanoDrop 2000 (Thermo Scientific). A 90 % recovery was achieved consistently. Recovered
antibodies were further diluted to 1 mg/mL and analyzed by DLS hydrodynamic diameter and
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zeta potential measurements using a Malvern Zetasizer Nano ZSP. Prior to the DLS
measurement, antibodies solutions were filtered using an Anotop 0.02-micron filter.
Antibody-AuNP Synthesis at Different pHs
AuNP-antibody conjugates were synthesized by first centrifuging 100 µL of AuNPs at
5000g for 5 min. Nanoparticle pellets were resuspended in 100 µL of 2 mM phosphate buffer of
pH 6, 6.5, 7, 8 and 9. Three micrograms of antibody (200 nM final concentration) was incubated
with 100 µL AuNPs at pH 6, 6.5, 7, 7.5, 8 and 9 in a low binding microcentrifuge tube for 3 h
with gentle agitation. After incubation, the AuNP-antibody suspension was centrifuged at 5000g
for 5 min to remove excess antibodies not adsorbed onto the AuNPs followed by resuspension in
buffer of the same pH. The conjugates were further purified by performing the
centrifuging/resuspension cycle three times.

Buffer pH 8

Size
Figure 1. Schematic illustration of conjugate synthesis at a pH 8.0 to form a stable monolayer.
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Titration of Antibody-AuNP Conjugates
Stable purified AuNP-antibody conjugate synthesized at pH 8.0 (Figure 1) was
centrifuged
at 5000g for 5 min. The supernatant was discarded whereas the pelleted conjugates were
resuspended in a buffer of pH 6 or 6.5 and allowed to stand for 4 and or 24 hours (Figure 2). The
pH of AuNP-antibody suspension resuspended in the various buffer solutions was determined
using litmus paper.
Antibody-AuNP Conjugate Unfolding Test
To determine the impact of AuNPs on antibody unfolding which can trigger nanoparticle
aggregation, we employed the use of an established immunoassay technique to assess the antigen
capture activity of antibodies adsorbed onto AuNPs. 100 µl of purified AuNP-antibody
conjugates were incubated with 3 µg of HRP for 1 h. After incubation, excess uncaptured HRP
was removed by centrifuging at 5000g for 5 min. The HRP captured conjugates were further
washed three times to ensure the removal of all free HRP. Enzymatic activity of HRP captured
by the conjugates was determined by the measuring the kinetics of oxidation of ABTS for 20
minutes, in a suspension made up of 10 µl HRP captured conjugates and 150 µl of ABTS using a
Bio-Rad microplate reader. A standard HRP calibration was used to extrapolate the
concentration of HRP captured by conjugates.
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Figure 2. Schematic illustration of titration of conjugates to lower pH.
Antibody-AuNP Characterization and Stability Analysis
UV-VIS characterization. Surface plasmon resonance of AuNP-antibody conjugate was
measured to evaluate the stability of the conjugates using a Cary 1 Bio UV−visible dual-beam
spectrophotometer with spectral bandwidth of 0.2 nm. For this experiment 80 µL of conjugate
was introduced into a microcuvette after which a UV-vis scan was obtained from 350 nm to 900
nm at 0.5 nm increments. An iMark microplate reader (Bio-Rad) was used in collecting
absorbance at 415 nm for the HRP enzymatic assay.
DLS sized and zeta potential measurements. A Malvern Zetasizer Nano ZSP operating with noninvasive back scatter optics was used to carry out conjugate size and zeta potential
measurements. A folded capillary cuvette was filled with desired buffer followed by careful
introduction of 20 µL of conjugate to the bottom of the cuvette by the aid of a capillary pipette
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tip. Before size and zeta potential measurements, the conjugates were equilibrated at 25 OC for
30 s. Conjugates size and zeta potential measurements were performed in triplicate and each
measurement consisted of the analysis sequence of size-zeta potential-size. This sequence was
adopted to confirm no aggregates were generated during the zeta potential measurement. For
each size and zeta potential measurement, fifteen separate runs were averaged.
Results and Discussion
Effect of pH on Antibody Triggered Aggregation of AuNPs
Mukherjee and co-workers31 reported the time evolution of protein corona on AuNPs
using cell lysate and a 20 nm AuNP. They observed a large particle size of about 200 nm during
the first 30 min of the incubation whereas a smaller conjugate with a size of 52-73 nm was
observed during later times. This observed phenomenon was attributed to the formation of
nanoparticle clusters resulting from bridging of protein between exposed sticky ends of AuNPs
at the initial stages of the incubation. Although this aggregation is reversible, proteins having
enough localized positive charge can strongly crosslink with negatively charged AuNPs to
facilitate irreversible aggregation. Cedervall et al38 analyzed the effect of IgG and fibrinogen
concentration on the aggregation of polystyrene nanoparticles. From their results, large
aggregates were observed when a low concentration of IgG was added to polystyrene
nanoparticles while no or small aggregates were observed at high concentration of IgG. The
generation of aggregates at low antibody concentration was ascribed to the bridging of IgG
between exposed ends of polystyrene nanoparticles since the nanoparticle surface is not fully
coated at low protein concentration. However, upon increasing the concentration of IgG, the
nanoparticle surface becomes fully saturated; hence, no exposed nanoparticle surface exists for
bridging to occur. Findenegg and co-workers41 also investigated the effect of pH and electrolyte
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concentration on the bridging aggregation of silica nanoparticles with lysozyme. They observed
aggregation of silica nanoparticles when pH was less than the isoelectronic point (pI) of
lysozymes. This observation was attributed to lysozymes acting as an electrostatic bridge
between silica nanoparticles due to an increase in positive surface exposed on lysozyme at a pH
below lysozyme’s pI. Here we seek to investigate the mechanism and effect of antibody surface
charge on AuNP aggregation.
To evaluate the impact of antibody surface charge on AuNP aggregation, we synthesized
AuNP-antibody conjugates at pHs ranging from 5.0-8.5. Excess antibodies were incubated with
citrate capped AuNPs for 4 h when synthesizing these conjugates (Figure 1). The resulting
antibody-AuNP conjugates were centrifuged to remove non adsorbed antibodies and its stability
was monitored using UV-vis spectrophotometry and dynamic light scattering to measure the
surface plasma resonance and the size of antibody-nanoparticle conjugates, respectively.

A

15

1.2

Normalized Abs

1
0.8
0.6
0.4
0.2
0
300

400

pH6

500

pH6.5

600
700
wavelenght (cm-1)
pH7

pH7.5

pH8

800

900

pH8.5

Figure 3. Evaluating the stability of antibody-AuNP conjugates at pH 6.0-8.5.
(A) Size distribution of MAHRP-AuNP conjugates synthesized at pH 6-8.5. (B) UV-visible
spectrum of MAHRP-AuNP conjugates synthesized at different pH by adding excess antibodies
to AuNP and incubating for 1 h.
A mean hydrodynamic diameter of 87 ± 4 nm was recorded for AuNP-antibody
conjugates at pH 7.5 and above, whereas conjugate sizes greater than 200 nm were observed for
conjugates synthesized below pH 7.5 (Figure 3A). Similarly, a broad and a red shifted SPR band
~ 9 nm was observed for conjugates synthesized below pH 7.5 (Figure 3B). In addition, the zeta
potential of nanoparticles became less negative upon protein adsorption. These results indicate
protein triggered aggregation of AuNPs at pH less than 7.5. We propose that protein surface
charge is therefore responsible for causing nanoparticles aggregation, thus, increased positive
patches on the surface of antibodies at lower pH may cause nanoparticles to aggregate.
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Overview of Nanoparticle Stability and Aggregation Mechanism
Nanoparticles in close proximity may interact with each other through short-range van
der Waals forces leading to the formation of clusters or aggregates.42,43 The aggregation of these
particles is both kinetically and thermodynamically controlled. While these theories can be
efficiently used to explain the stability of many colloidal particles, it also provides significant
insight on nanoparticle stability with extended modification.44 For the kinetic model,
nanoparticles must collide inelastically to promote aggregation. The collision rate depends on the
root mean velocity, the number density of nanoparticles, temperature, and the energetics
(repulsive and attractive forces) of the particles. Thermodynamically controlled aggregation of
AuNPs is mostly explained using Derjaguin–Landau–Verwey–Overbeek (DLVO) theory, which
calculates the total interaction potential between two particles as a function of their radius of
curvature and the distance between them.42 Electrostatic repulsive forces and van der Waals
attractive forces are assumed to be the most predominant interactions that exist between these
particles in the DVLO theory. One of these two interactions is more significant, depending on
the distance between the particles. Thus, electrostatic repulsive forces that depend on the Debye
length predominate at a longer distance, whereas van der Waals attractive forces predominate at
a certain shorter distance. Nanoparticle Zeta potential directly correlates with the Debye length
and it is mostly employed in calculating the surface potential in DVLO theory, hence can be used
to predict the nanoparticle stability threshold.
Additionally, steric interactions, osmotic potential resulting from competition between
solvent molecules to solvate proteins on AuNPs within a distance lower than two times the
monolayer thickness of protein,45,46 and elastic interaction between proteins at a distance less
than the monolayer thickness of proteins, also play a critical role in the stability of the protein
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functionalized nanoparticle. From these theories, you can predict the experimental requirement
needed to maintain nanoparticle stability in solution. Consequently, in this chapter we seek to use
the above theories to explain our experimental results in order to establish the mechanism by
which protein induces nanoparticle aggregation.
Several mechanisms have been proposed for protein-induced nanoparticle aggregation
using kinetic and thermodynamic models.26,37–39,43,47 Among these mechanisms, electrostatic
bridging, van der Waals attraction of nanoparticles resulting from surface charge depletion upon
protein adsorption,26,42 and protein unfolding 3623,37,48are the most discussed. The aggregation of
AuNPs by antibodies may proceed either through the bridging of localized positively charged
surface of antibodies with negatively charged citrate capped AuNPs, by the reduction of AuNPs
surface charge when citrates are displaced by antibodies or by the hydrophobic interaction
between unfolded proteins on nanoparticles.
pH Effect on Antibody Surface Charge
Immunoglobulin G (IgG), the most abundant antibody in serum of vertebrates, is a
globular glycoprotein with a molecular weight of about 150 kDa produced by plasma B cells. It
is made up several amino acids, including basic amino acids such as arginine, lysine, and
histidine.52 Most of these basic amino acids are relatively solvent accessible; hence their side
chains can be easily protonated or deprotonated depending on the pH of a solution. The surface
charge of IgG can, therefore, be substantially altered by pH, as protonation of these amino acids
creates positive charges, which results in positive patches on the surface of the protein.
Initially, to affirm our hypothesis of the impact of pH on antibody surface charge, we
conducted a computational simulation of IgG (PDB-ID 1IGT) surface charge with an online
molecular dynamics platform using adaptive poison Boltzmann solver (APBS) (http://nbcr-
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222.ucsd.edu/pdb2pqr/).49,51 As shown in Figure 4, with red and blue indicating regions of
negative and positive charges, respectively, pH has a significant impact on IgG surface charge.

pH 6.0

pH 6.5

pH 7.5

Figure 4. Computational simulation of mouse IgG 2a antibody surface charge at four different
pHs. Blue and red regions represent positive and negative potential, respectively, in a range of −5
kbT/e to + 5 kbT/e. The calculations were performed online using Adaptive Poison Boltzmann
Solver (APBS). http://nbcr-222.ucsd. edu/pdb2pqr/.49–51
The effect of pH on IgG surface charge was evaluated experimentally to examine our
hypothesis. In this experiment, a mouse monoclonal anti-HRP (MAHRP) IgG was suspended in
buffers of pH 5, 7, 8 and 9. The zeta potential, as well as the size of IgG, were measured using a
Zetasizer Nano ZSP (Malvern instruments). We recorded a decrease in the negative zeta
potential of MAHRP as the pH decreases. Thus, zeta potentials of -13.68, -9.39, -6.67 and, -0.21
mV were recorded at pH 9, 8, 7 and 5, respectively. Additionally, there was no significant
change in protein size at different pHs (Table 1). These results indicate a significant alteration of
IgG surface charge by solution pH whilst maintaining antibody integrity. Moreover, there was no
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significant change of protein size before and after zeta potential measurement as shown in Table
1, confirming no aggregation of proteins during the zeta potential measurement.

Table 1. DLS size and zeta potential of anti-HRP antibody (MAHRP) at different pHs.
pH

Average Size

Average Zeta

Average Size

(2 mM /0.3% NaCl)

Before Zeta (nm) Potential (mV)

After Zeta (nm)

5

14.65

-0.21

13.31

7

13.80

-6.67

12.95

8

16.32

-9.39

17.00

9

14.73

-13.63

14.11

Effect of Antibody Unfolding on Nanoparticle Aggregation
The unfolding of proteins upon adsorption onto nanoparticles has also been proposed as
one of the mechanisms that can drive nanoparticle aggregation. Link et al. recently reported that,
BSA induced the aggregation of nanoparticles by a BSA-BSA interaction; thus, unfolding of
BSA upon adsorption to nanoparticles exposed hydrophobic surface that can interact with other
exposed BSA hydrophobic sites leading to nanoparticle aggregation. To this end, we probed the
effect of antibody unfolding on nanoparticle aggregation by measuring its antigen binding
activity, hypothesizing that the antigen binding capabilities of antibodies will be lost if the
antibody unfolds. Here, stable purified AuNP-mouse anti-HRP conjugates resuspended in buffer
of pH 6, 6.5, and 8 for 24 h were incubated with HRP for an hour and the enzymatic activity of
HRP captured by AuNP-mouse anti-HRP conjugates was analyzed by an ABTS HRP assay.
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From the enzymatic rates measured, (Figure 5) MAHRP-antibody adsorbed onto AuNPs was
still active for antigen capture. This result suggests no drastic unfolding of antibodies adsorbed
onto AuNPs that can trigger nanoparticle aggregation.

300

HRP/AuNP

250
200
150
100
50
0
6

6.5
pH

8

Figure 5. Quantitation of antigen binding activity of conjugates after resuspension into buffer of
pH 6, 6.5 and 8. MAHRP-AuNP conjugate synthesized at pH 8 is resuspended in buffer of pH 6,
6.5 and 8.5 for 24 hours.
Buffer Exchange of Stable Antibody-AuNPs to Lower pH
In order to establish the mechanism by which antibody surface charge induces
nanoparticle aggregation, a stable conjugate synthesized at pH 8.0 was titrated to lower pH by
resuspension in buffer of pH 6 and 6.5 for four and twenty-four hours, after which the size
(Figure 6), surface plasmon resonance (Figure 7A and 7B) and zeta potential (Figure 7C) of
the conjugates were measured. Titration to lower pH was conducted to alter the adsorbed protein

21

surface charge, which, in effect, decreases the overall negative charge of the conjugates. We
anticipated that if the mechanism of protein triggered aggregation proceeds by the reduction of
the surface charge of nanoparticles, which may reduce the diffusion bilayer layer, then the
nanoparticles are expected to aggregate upon titration to lower pH.
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Figure 6. Size and particle distribution of MAHRP-AuNP conjugates synthesize at pH 6.0-8.5 in
situ and stable conjuagtes titrated to pH 6.0-8.0. (A) Size of conjugates in nm for in situ
synthesis and titrations. (B) Polydispersity Index (PDI) of in situ and titration conjugates. (C)
DLS size.
However, there was no change in the size (Figures 6) and surface plasmon resonance (Figures
7A and 7B) even after the conjugates was resuspended in buffer of pH 6 and 6.5 for 24 hours.
The results therefore, indicate no aggregates was formed after titration to lower pH.
Additionally, the results suggest reduction of the total nanoparticle surface charge by
adsorbed antibodies or proteins is not the prevalent mechanism that causes nanoparticles to
aggregate. Meanwhile, aggregates are also observed when excess antibodies are incubated with
AuNPs at lower pH. Furthermore, when stable conjugates synthesized at pH 8.0 are resuspended
in a lower pH buffer the overall negative potential on the conjugates is expected to decrease as
more ionizable side chains are protonated. However, no significant change in zeta potential was
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Figure 7. Surface plasmon resonance and Zeta potential of conjugates after titration into buffer
of pH 6.0 and 6.5. (A) UV-visible spectra of MAHRP-AuNP conjuagtes synthesized at pH 8.0
and resuspended in buffer of pH 5.0-6.5 for 4 hours. (B) UV-visible spectra of MAHRP-AuNP
conjuagtes synthesized at pH 8.0 and resuspended in buffer of pH 5.0-6.5 for 24 hours. (C) Zeta
potential of conjugates after resupesnion in buffer pH 6.0 , 6.5 and 8.0 for 4 and 24 hours.
observed for our conjugates (Figure 7C). From these results, we inferred that, as the diffusion
bilayer decreases upon resuspension of conjugates in a buffer of lower pH, steric interactions,
including osmotic potential becomes significant at a distance less than twice the monolayer
thickness.44,47 These repulsive forces from adsorbed proteins contribute to the overall surface
potential, which causes resistance to the collapse of diffusion bilayer and prevents the
nanoparticle from aggregating. Additionally, the nanoparticle surface is fully saturated when
incubated with excess antibody at pH 8.0, hence, there is no exposed surface for an antibody
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with sufficient positive charge to act as an electrostatic bridge when resuspended at lower pH.
These observations suggest AuNP aggregation at lower pH is a result of electrostatic bridging by
antibodies.
Effects of Titration with NaOH on Reversibility of Aggregates
As discussed above, incubation of excess antibodies with citrate capped AuNPs at pH
less than 7.5 triggers aggregation of the nanoparticles. To probe the reversibility of these
aggregates over time, excess antibodies were added to 100 ml of AuNPs at pH 6.0 and 6.5 and
the size of the aggregates was monitored after 5 min, 30 min, 5 h, and 24 h. As seen in Figure 8,
large aggregates of nanoparticles were observed for all time points. The persistence of these
aggregates over a period of 24 hours implies no propensity toward reversibility. However, upon
addition of 0.1 M NaOH the color and size of the nanoparticles incubated with antibodies
reversed to a normal stable conjugate size and color for samples incubated from 5 min to 5 h. A
significant amount of aggregates was still present for the 24 hours incubation even after the
addition of 0.1 M NaOH. From these observations we inferred that, aggregates are observed as a
result of electrostatic bridging of positive patches on antibodies as pH decreases to negatively
charged AuNPs for the first 5 hours since the change in antibody surface charge by the addition
of NaOH leads to the reversibility of the aggregates. Nonetheless when these aggregates are
allowed to stay for 24 hours van der Waals attraction between adjacent AuNPs held together by
antibodies now overtake the electrostatic bridging hence the protein surface charge has no effect
on the aggregate formation.
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Reducing Antibody Positive Charge through Chemical Modification Allows Synthesis of
Conjugates at Lower pH
The total surface charge of proteins is determined by the number and identity of ionizable
side chains of its amino acids. Primary amines of lysine residues are mostly protonated at and
below physiological pH, which increases the total positive charge on the protein surface. When
these lysine residues are acroleinated, they lose the potential to possess a positive charge even at
acidic pH. Mouse anti-HRP antibody was reacted with excess acrylic acid N-hydroxy
succinimide (NHS) to acroleinate most solvent-accessible lysine residues. The extent of the
antibody surface charge alteration upon chemical modification was monitored by measuring the
antibody zeta potential before and after the chemical modification. The zeta potential of antibody
decreased from -7.85 mV to -17.13 mV after chemical modification.
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Figure 8. Reversibility of aggregation by addition of NaOH. (A) DLS Size distribution of
conjugates synthesized at pH 6.0 (in situ) for 4 and 24 hours and titrated to higher pH by addition
of 0.1 M NaOH. (B) DLS size distribution of conjugates incubated at pH 6.5 (in situ) for 4 and
24 hours. Dash lines represent size distribution of antibody-AuNP conjugates after addition of
0.1M NaOH.
UV-Vis analysis of AuNP antibody conjugates synthesized by incubating excess
chemically modified antibodies with AuNPs revealed that the conjugates were stable at pH less
than 7.5 (Figure 9). This result suggests that the protein surface charge controls the stability of
AuNPs in solution. Moreover, the ability to synthesize stable AuNP antibody conjugates at lower
pH after knocking out some of the positive charges on antibody suggests electrostatic bridging of

28

antibodies to citrate capped AuNPs to be the predominant interaction initiating the irreversible
aggregation of AuNPs.
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Figure 9. Surface plasmon resonance of acrylic acid NHS chemically modified MAHRP-AuNP
conjugate synthesized in situ at pH 6.0, 6.5 and 7.5.
Conclusion
In summary, this study provides insight into the mechanism responsible for antibody
induced AuNP aggregation. By using two different approaches to generate AuNP-antibody
conjugates at different pH levels, we have proven the effect of protein (antibody) surface charge
on AuNP stability. Several mechanisms have been proposed for protein triggered nanoparticle
aggregation, here we confirm electrostatic bridging to be the prevalent mechanism by which
antibodies induce AuNP aggregation at pH below 7.5. Also, we reaffirm steric interactions as
one of the potentials contributing to the stability of protein functionalized AuNPs as proposed by
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several theoretical models.44–46 These findings support our hypothesis that pH plays a critical role
in solution phase AuNP-antibody conjugate synthesis.

30

CHAPTER III: HIGH AFFINITY POINT OF INTERACTION ON ANTIBODY ALLOWS
SYNTHESIS OF STABLE AND HIGHLY FUNCTIONAL ANTIBODY-AuNP
CONJUGATES
Introduction
Enzyme-linked immunoassays (ELISAs), fluoroimmunoassays, and radioimmunoassays,
have thoroughly been exploited for the detection of various disease biomarkers and infectious
agents.4,53,54 Although these assays are quite efficient, they require highly skilled personnel,
specialized laboratories, long experiment times, and sometimes hazardous radiolabels. These
limitations restrict the use of these assays for high throughput screening and point of care
diagnosis. Recently various laboratories have employed AuNPs as sensing agents and
heterogeneous labels for immunoassays17,55 due to their unique optical and surface properties56.
When incorporating AuNPs into immunoassays, the antibody or protein of interest must first be
conjugated to the AuNPs. Various immobilization techniques, including covalent immobilization
of antibody onto AuNP, direct antibody immobilization, and directionally oriented
immobilization,12,16,54,57,14,58 have been used to conjugate antibodies and other proteins onto
AuNPs. Even though these conjugation techniques are promising, they present several
challenges; including randomized orientation of bound targets, inefficient immobilization,
aggregation, and sometimes protein unfolding.
Recently, our lab determined the effect of pH on the orientation of mouse monoclonal
anti-horseradish peroxidase (MAHRP) antibody on citrate capped AuNPs. From our findings, the
amount of available antigen-binding sites of antibodies on AuNPs increases with decreasing pH
of the antibody-AuNP conjugation solution.40 Thus, more antibodies were oriented correctly as
the pH decreases. Our results suggest that lower pH improves the orientation of antibodies on
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AuNPs; meanwhile, aggregation of AuNPs was observed below pH 7.5. In order to access lower
pHs and improve antibody orientation, we have elucidated the mechanism by which this
aggregation occurs at lower pH. Electrostatic bridging of antibodies to citrate capped AuNPs
resulting from increased positive charged patches on antibody surface at acidic pH was
determined to be the predominant pathway through which antibodies trigger AuNP aggregation.
In summary, we have established that antibody surface charge is a critical parameter that controls
both orientation and stability of antibody-AuNP conjugates.
Antibodies ubiquitously contains lysine residues, which contribute to its total surface
charge depending on the pH of the solution. For example, almost all solvent accessible lysine
residues are protonated and, therefore, positively charged at a pH below 7.0. Chemical
modification of antibodies through reaction with lysine residues can, therefore, help mitigate
charge effects that cause nanoparticle aggregation and enable the synthesis of highly oriented
conjugates at lower pH. To this end, we have employed various chemical modifications to
antibodies to help reduce the extent of positive charge, increase the points of interaction, and
enhance conjugate stability.
Electrostatic interaction between proteins and nanoparticles is established as the initial
driving force that facilitates the conjugation of proteins to AuNPs.59,58,60 As these proteins and
nanoparticle come into close proximity, cysteine residues interacts with AuNPs to form a Au-S
bond.18,35,61 Whereas free thiol is well established to form a stable covalent bond with AuNPs,
amines have also been reported as a ligand for gold.21,55 Here, we have employed several
chemical modifications to lysine residues of antibodies to help identify and establish the
chemical interactions that enable irreversible conjugation of antibodies to AuNPs. The kinetics
of antibody corona formation (soft and hard) of both unmodified (native mouse anti-HRP)
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antibody and chemically modified antibodies were also investigated using dynamic light
scattering (DLS). We forecast that the identification of essential functionalities on proteins that
interact with AuNPs will enable the synthesis of highly stable and orientated protein
functionalized AuNPs.
Materials and Methods
Reagents
A 60 nm AuNP (Ted Pella Inc., Redding, CA) was employed in all studies. Mouse
monoclonal anti-HRP IgG antibody (Clone 2H11) was obtained from My BioSource. ABTS (1step ABTS), HRP, and dithiobissuccinimidyl propionate (DSP) were purchased from Thermo
Scientific (Rockford, IL). ThermoFisher Scientific CBQCA protein quantification kits were used
for antibody fluorescence assay validation. Phosphate buffers were prepared using anhydrous
potassium phosphate dibasic and potassium phosphate monohydrate obtained from Mallinckrodt
Chemicals, Inc. (Paris, KY) and Fischer Scientific (Fair Lawn, NJ), respectively. Acrylic acid Nhydroxysuccinimide ester (NHS-acrylic acid) and Amicon ultracentrifugal filter (MWCO 100
kDa) was acquired from Sigma-Aldrich (St Louis, MO).
Computational Simulation of Antibody Surface Charge
Adaptive Poison Boltzmann Solver (APBS) was used to calculate the surface charge of
unmodified and lysine modified antibodies. Acetylated amines were parametrized using a
cGenFF forcefield. The PDB file (PDB-ID 1IGT) obtained from RSCB Protein Data Bank
(https://www.rcsb.org/) was converted to PQR using a PDB2PQR webserver
(http://server.poissonboltzmann.org/). The conversion of PDB to PQR replaces the occupancy
column and temperature factor in PDB with atomic charge (Q) and radius (R), respectively.
Also, PDB2PQR adds all missing hydrogen and heavy atoms and assigns coordinate values to
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them. All amino acid residues were parameterized using a CHARM forcefield. PROPKA was
used to assign protonation states of ionizable groups at a particular pH.
Antibody Chemical Modification and Characterization
Activated ester acrylic acid N-hydroxy succinimide (NHS) and dithiobis(succimidyl
propionate) (DSP) were used as antibody chemical modifiers. Two µL of 50 mM DSP reduced
and acrylic acid NHS were added to 50 µg of mouse anti-HRP (MAHRP) antibody in separate
reaction vials. The chemical modifier antibody solution reacted for 2 hours at room temperature
with gentle shaking. Excess unreacted chemical modifiers were removed by the use of an
Amicon Ultra Centrifuging filters (MWCO 100 kDa). Five hundred microliters of 2 mM
phosphate buffer pH 7.5 was used to rinse out glycerol on the filter membrane by centrifuging at
10000 g for 5 minutes. The antibody chemical modifier reaction mixture was diluted to 500 µL
and centrifuged at 14000 g for 12 minutes. The reverse spin capabilities of filter allowed it to be
turned upside and centrifuged at 1000 g for 3 minutes to decant modified antibodies.
A NanoDrop 2000C spectrophotometer (Thermo Scientific, Rockford, IL) was used to measure
the concentration of modified antibodies. The extent of chemical modification was monitored by
measuring the zeta potential of the antibody before and after chemical modification using a
Zetasizer Nano (Malvern Instruments).
Equilibrium dialysis and an HRP enzymatic assay were used to evaluate the antigen
binding potential of chemically modified antibodies. Fifty microliters of 1.0 mg/mL (6.7 nM) of
chemically modified, unmodified antibodies and mouse IgG isotype control was loaded into one
chamber of the equilibrium dialysis tube (MWCO 100 kDa). The other chamber was filled with
0.45 µg/mL (9.9 nM) of HRP and allowed to equilibrate for three hours. After equilibration,
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30µL of solution from the chamber originally filled with HRP was withdrawn and subjected to
HRP/ABTS enzymatic assay.
Antibody-AuNP Synthesis
One hundred µL of 60 nm AuNPs were pelleted by centrifuging at 5000 g for 5 minutes.
The pelleted AuNPs were resuspended in 100 µL of buffer of required pH after which 3 ug of
desired antibody (chemically modified or unmodified) were added. For full protein saturation on
AuNP, unmodified and DSP modified antibodies were incubated with AuNPs at room
temperature for an hour while NHS modified antibodies were allowed to react with AuNPs for
24 hours.
Kinetic of Antibody Adsorption onto AuNPs
To study the time evolution of antibody corona on AuNPs, 3 mg of desired antibody
(chemically modified or unmodified) were added to 100 µL of AuNPs in a low binding
centrifuge tube and incubated for 1, 3, 6, 12, and 24 h. The size and zeta potential of the
conjugates were measured in situ, thus without centrifugation. The conjugates were centrifuged
at 5000 g for five minutes and the supernatant was discarded followed by resuspension in buffer
of desired pH. The centrifugation/resuspension cycle was carried out three times to ensure the
removal of any non-adsorbed antibody. The size and zeta potential of antibody-AuNPs
synthesized at each time point were measured after purification.
Quantifying the Number of Antibodies bound Per AuNP
A native protein fluorescence assay was used to quantify the number of proteins adsorbed
onto AuNP. Antibody-AuNP conjugates were purified to remove excess antibodies in solution
by centrifuging at 5000 g for 5 minutes, the supernatant was removed by carefully pipetting the
clear solution from the pellets. Pelleted antibody-AuNPs were resuspended in buffer of desired
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pH and centrifuged at 5000 g for 5 minutes followed by decantation of supernatant. Three cycles
of centrifugation/resuspension were carried out to certify the removal of any non-adsorbed
antibody. To digest the gold and release antibodies into solution for easy protein quantification,
10 µL of 100 mM potassium cyanide was added to the pelleted antibody-AuNP conjugates. The
reaction mixture was diluted to 110 µL with a 2 mM phosphate buffer (pH 7.5) after 2 hours of
reaction at room temperature. Standard solutions of chemically modified and unmodified antiHRP antibody (0-5 mg/mL) were prepared in a digested AuNP solution containing the same
concentration of AuNP and KCN as in antibody-AuNP conjugates. Florescence spectra of
standards and conjugates were obtained using an excitation wavelength of 280 nm and an
emission range of 320-350 nm. Florescence intensity in the range of 335-342 nm was integrated
and used for antibody quantification. To validate the native florescence assay we employed, a
CBQCA (3-(4-carboxybenzoyl) quinoline-2-carboxaldehyde) highly sensitive florescence assay.
For the CBQCA experiment, 10 µL of a 100 mM KCN was used to digest the pelleted antibodyAuNP conjugates for 2 hours. A 0.1 M phosphate buffer (pH 9.3) was used to dilute samples to
150 µL. Standard calibration solutions (0.5-5 µg/mL) of unmodified mouse anti-HRP antibody
were prepared for the CBQCA florescence assay as well. To each standard concentration and
sample was added 10 µL of 5 mM CBQCA reagent followed by incubation at room temperature
for 2 hours. Aluminum foil was used to cover the samples and standards during incubation to
prevent exposure to light. After incubation, protein florescence was measured at an excitation
and emission wavelength of 465 and 550 nm, respectively.
The amount of AuNPs to which antibody is adsorbed was also determined using a Perkin
Elmer optima 7300 V inductively coupled plasma-optical emission spectroscopy (ICP-OES).
Fifty µL of digested antibody-AuNP conjugates used for the antibody florescence assay were
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diluted to 5 ml with 2% HNO3. Standard solutions of gold (0.1 – 1 mg/L) were prepared in 2%
HNO3. The number of AuNPs was calculated by dividing the mass of total gold extrapolated
from ICP-OES standard calibration by the mass of a 60 nm AuNP (2.18 × 10#!$ 𝑔 ).
Quantitation of Conjugates Antigen Binding Site
The antigen binding activity of antibodies adsorbed onto AuNPs was determined by an
HRP enzymatic assay. One hundred mL of purified antibody-AuNP conjugate were incubated
with 3 mg of HRP for 1 hour. Excess unbound HRP was removed by three centrifuge/wash
cycles at 5000g for 5 mins. Standard concentrations (0.1-0.7 µg/mL) of HRP were prepared and
used to quantify the amount of HRP captured by conjugates. A 10 µL aliquot of standards and
conjugates was mixed with 1-step ABTS solution. The enzymatic rate was determined by
measuring the absorbance of the oxidized product at 415 nm for 20 mins at 10 s intervals using
Bio-Rad microplate plate reader. To correlate the number of HRP captured to the number of
antibodies per AuNP, the exact number of AuNPs present in the 100 µL antibody-AuNP
conjugate suspension used for the HRP assay was determined using an ICP-OES.
Dissecting Antibody Orientation on AuNP
To determine the impact of overcrowding of antibodies on AuNPs on antigen capture,
the enzymatic activity of conjugates formed by incubating different concentrations of
unmodified anti-HRP antibodies was evaluated. For this experiment, 1.5, 2, 3 and 4 mg of
unmodified anti-HRP antibody was added to 100 µL of AuNP in a 2 mM phosphate buffer (pH
7.5). The antibody-AuNP suspension was left to incubate for an hour. After incubation, the
number of antibodies per AuNP and antigen binding site was determined using the procedures
discussed above. Three µL of a 1 mg/mL solution was incubated with purified conjugates before
HRP incubation to block all available AuNP surface.
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Instrumentation
Dynamic Light Scattering (DLS). Hydrodynamic diameter and zeta potential of chemical
modified, unmodified antibodies, and conjugates were measured using a Zetasizer Nano ZSP
(Malvern Instruments) equipped with non-invasive back scatter optics. Antibodies were filtered
with a 0.02 µm filter prior to DLS analysis. A capillary cuvette was filled with filtered buffer and
a 20 µL aliquot of antibodies or conjugates was carefully introduced to the bottom of the cuvette.
Hydrodynamic diameter and zeta potential were measured in triplicate. Fifteen runs were
averaged for each measurement. A built-in Smoluchowksi method for aqueous media was
adopted for all DLS measurement.
UV-visible Measurement. A Cary 1 Bio UV-visible dual-beam spectrophotometer was used to
obtain extinction spectra of protein-AuNP conjugates. The spectra were collected over a range of
350-900 nm at 0.5 nm increment with a spectral bandwidth of 0.2 nm. HRP enzymatic assay
absorbance was collected using an iMark Bio-Rad high throughput microplate reader. Enzyme
kinetics was monitored at 415 nm for 20 mins at 10 s intervals.
Results and Discussion
Antibody Chemical Modification
Primary amines of lysine can act as efficient nucleophiles at a basic pH, which can react
with electrophiles with good leaving groups. The product of this addition-elimination reaction
prevents protonation of lysine residues at lower acidic pH as well as the interaction of primary
amines with other ligands. Chemical modification of antibodies through the reaction of primary
amines eliminates its positive charge, thereby decreasing the overall positive charge on the
surface of antibodies. In order to substantiate that chemical modification of lysine alters antibody
surface charge, lysine residues of a fully characterized IgG (PDB-ID 1IGT) were acetylated in-
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silico using UC-Chimera, and its surface charge computed using a Poisson Boltzmann solver on
CHARM-GUI.62,63 The results indicate a decrease in positive surface charge for modified
antibody compared to the unmodified antibody, as shown in Figure 10 with blue and red patches
denoting regions of positive and negative charges, respectively.

Unmodified
pH 7.5

Modified pH
7.5

Figure 10. Calculation of antibody (PDB-ID 1IGT) surface charge. Adaptive Poison Boltzmann
equation solver on a CHARM-GUI was used for protein surface charge simulation. Blue and red
regions represent positive and negative potential, respectively, in a range of −5 kbT/e to + 5
kbT/e.
Antibody chemical modification was carried out experimentally using acrylic acid Nhydroxy succinimide (acrylic acid NHS) and reduced dithiobissuccinimidyl propionate (DSP).
We envisaged that acrolein and a thio propionate group will be covalently bonded to primary
amines of lysine residues upon reacting with acrylic acid NHS and reduced DSP, respectively
(Figure 11). A Malvern Zetasizer Nano ZSP was employed to monitor the extent and effect of
chemical modification on antibody surface charge by measuring the protein zeta potential. As
anticipated, the surface charge on the unmodified antibody increases (becomes less negative) as
the pH decreases, as a result of protonating basic amino acids (Figure 12). Importantly, both of
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the modified antibodies present a substantially more negative surface charge at pH 7.5 than the
unmodified antibody at a similar pH. These data confirm chemical modification of lysine
residues through the primary amine and establish that antibody surface charge can be
manipulated via chemical modification.
Although both chemical modifiers used can alter antibody surface charge, DSP increases
the number of free thiols, thereby promoting strong conjugation to AuNPs. Thus, the DSPmodified antibody was further characterized to determine the extent of chemical modification by
measuring the number of additional free thiols on the protein. Molecular modeling of an IgG
protein (PDB-ID 1IGT) establishes that the thiols of the cysteine residues are all involved in
disulfide bonds and not present as free thiols (Figure 13).
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Figure 11. Chemical modification of the lysine residue with acrylic acid NHS (top) and reduced
DSP (bottom).
The number of free thiols on the unmodified protein were quantified using Ellman’s
reagent and a previously established protocol (Figure 14).64 No free thiols were detected on the
unmodified antibody, consistent with molecular models showing that each cysteine residue is
involved in a disulfide bond and therefore not detectable by Ellman’s reagent. However, ten free
thiols were detected for each DSP-modified antibody. These results further confirm chemical
modification of the antibody and show that free thiols can be added to proteins which may
impact their adsorption to AuNPs.
Equilibrium dialysis was performed to examine the antigen-binding activity of the antiHRP antibodies before and after chemical modification.
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Figure 12. Characterization of chemically modified and unmodified antibodies. Zeta potential of
unmodified chemically modified antibodies at different pHs.

Figure 13. Structure of antibody showing all cysteine residue (pink) are engaged in disulfide
bond.
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Figure 14. Characterization of chemically modified and unmodified antibodies. The number of
free thiols on unmodified and DSP-modified antibodies determined using Ellman’s reagent.
To this end, an HRP solution was added to one chamber of the dialysis device and an equimolar
concentration of sample was added to the adjacent chamber. The sample solutions included
unmodified anti-HRP antibody, DSP-modified anti-HRP, NHS-modified anti-HRP, an IgG
isotype control, and buffer. The chambers were separated by a 100 kDa membrane and
equilibrated for 3 h to allow HRP (MW 44 kDa) to equilibrate between the chambers while the
IgG was confined to its original chamber (MW 150 kDa). After equilibration, the solution was
removed from the chamber originally filled with HRP and the remaining HRP was measured
based on enzymatic activity for the substrate ABTS. Figure 15 shows that no enzymatic activity
was observed for the unmodified or either modified antibody. This result confirms the antibody
binds the HRP antigen and extracts it from its original chamber. For the IgG isotype control and
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buffer, the HRP solution equilibrates in both chambers to equal concentrations since no binding
occurs to concentrate the HRP in the sample chamber; thus, significant enzymatic activity is
observed for the equilibrated solution removed from the HRP chamber, as is evident in Figure
15. The results suggest no decrease in antigen binding affinity of antibodies after chemical
modification as unmodified and chemically modified antibodies had similar enzyme kinetic rates
after equilibrating with HRP. Likewise, there was no significant change of protein size (16 ± 2)
nm observed by DLS before and after chemical modification indicating a low possibility of
protein unfolding upon chemical modification.
4

HRP Enzymatic Activity
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Samples
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Figure 15. Characterization of chemically modified and unmodified antibodies. Result of
equilibrium dialysis to determine the antigen-binding activity of the unmodified (UM) and
modified antibodies (NHS and DSP). Negative control samples include an IgG isotype (ISCTR)
control and buffer (EQ CONC).
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Kinetics of Hard and Soft Antibody Corona Formation on AuNPs
Previously, we have determined that a monolayer coverage of anti-HRP antibodies is
formed on AuNPs within an hour. To this end, excess chemically modified and unmodified
antibody were incubated with AuNPs for 1h at pH 7.5. UV-vis spectrophotometry, dynamic light
scattering (DLS), and nanoparticle tracking analysis (NTA) were used to measure the presence
and thickness of the antibody monolayer.
Upon the adsorption of proteins, the refractive index of AuNPs changes. This change in
refractive index results in a shift in extinction maximum of the nanoparticle surface plasmon
resonance, which can be monitored using a UV-Vis spectrophotometer. Unconjugated 60 nm
AuNPs exhibited an extinction maximum at 536 nm (Figure 16). An extinction maximum was
observed at 540-541 nm for the 60 nm AuNPs incubated with unmodified and DSP-modified
antibody for 1 h (Figure 6). This 4-5 nm red shift is characteristic of an adsorbed protein
monolayer. Surprisingly, however, no shift in the extinction spectrum was observed for the 60
nm AuNPs incubated with the NHS-modified antibodies, and this result suggests that the NHSmodified antibody did not adsorb onto the AuNP within the 1 h incubation period.
DLS size and zeta potential measurements corroborate the UV-visible spectrophotometry
results. An increase in size and a decrease in the zeta potential of AuNPs is observed when
proteins are adsorbed on nanoparticles. DLS analysis confirms a monolayer thickness of 20 nm ±
5 nm and 14 nm ± 3 nm for the DSP-modified and unmodified antibody AuNP conjugates after
purification. Meanwhile, no significant change in AuNP size was detected for NHS-modified
antibody AuNP conjugates for the one-hour incubation time.
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Figure 16. Extinction spectra of Antibody-AuNP conjugates incubated for an hour.
To understand why there was no adsorption of NHS-modified antibodies onto AuNPs at
an hour of incubation, we investigated the time evolution of the soft and hard antibody corona on
AuNPs. Both hard and soft protein coronas have been established to be present in AuNP protein
conjugates. A thiol gold bond is well-established to be responsible for the hard corona formation.
In contrast, electrostatic interaction between gold and charged surfaces of proteins facilitate the
formation of the soft corona. It has been shown that centrifugation can remove the soft protein
corona while the hard corona remains adsorbed.20,31,65 Herein, we employed centrifugation
(Figure 17) and DLS size measurements to probe the time evolution of the soft and hard
antibody corona on a AuNP. Antibody AuNPs size and zeta potential were monitored for 24
hours using a Zetasizer Nano ZSP (Malvern Instrument). AuNP-antibody conjugates size was
measured before and after centrifuging. Conjugate size measured before centrifuging represents
both hard and soft corona of antibody. In contrast, only hard corona remains after centrifuging.
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The change in antibody-AuNP conjugates size for chemically modified and unmodified
antibodies after centrifuging represents the soft corona thickness at each time point (Figure 18).
A soft corona of antibodies was observed within an hour of incubation for both
chemically modified and unmodified antibody-AuNP conjugates. There was no considerable
difference in the thickness of the antibody soft corona for all time points. Nonetheless, after
centrifuging to remove the soft corona, the unmodified and DSP modified antibody-AuNP
conjugates recorded the presence of antibody hard corona on AuNP at all time point (Figures
18A and 18C). The size of acrylic acid NHS modified antibody-AuNP conjugates returned to 62
nm for the 1, 3 and 6 h (Figure 18B) time points after centrifuging, signifying the absence of
antibody hard corona for these incubation time.
Similarly, Zeta potential of purified conjugates suggests the rapid formation of hard antibody
corona for unmodified and DSP modified antibodies, where NHS modified antibodies only
showed a substantial change in AuNP Zeta potential at 12 hours and beyond (Figure 19).
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Figure 17. Time evolution of antibody corona on AuNP. Demonstration of effect of centrifuging
on antibody soft and hard corona.
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These results suggest that electrostatic attraction between antibodies and AuNP which facilitate
soft corona formation as well as the initial coordination of proteins to nanoparticles is rapid.
Although the free thiol of the cysteine residue forms a stronger bond with gold and is the
most preferred ligand, amines have been shown to display moderate affinity toward gold.66–68,21
Computational analysis of a fully characterized IgG2A (PDB ID 1IGT) similar to our antibody
revealed all cysteine residues to be engaged in disulfide bonds (Figure 13). In contrast,
numerous solvent-accessible lysine residues were identified. We inferred from the computational
studies that AuNPs would initially interact with readily available primary amines of antibody
lysine residues.
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Figure 18. Kinetic of hard and soft antibody corona formation. (A) DLS size meaured of
unmodified antibody-AuNP conjugates before removal of excess antibodies through
centrifugation (in situ) and after removal of excess antibodies (purified). (B) Size of acrylic acid
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NHS-modified antibody-AuNP conjugates in situ and after purification. (C) DSP- modified
antibody-AuNP conjugates size before (in-situ) and after (purified) purification.
The formation of the hard antibody corona on AuNPs was not observed until 12h for the
acrylic acid NHS modified antibody; meanwhile, a soft corona of acrylic acid NHS modified
antibody was formed under 1 hour. From this observation, we suggest primary amines to be an
essential functional group to promote adsorption of proteins onto AuNPs in the absence of free
thiol. The DSP-modified antibodies readily formed a stable hard corona within an hour (Figure
18C) with a small change in conjugate size after centrifuging, demonstrating a rapid formation of
gold sulfur bond by the free thiol.
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Figure 19. Zeta potential of unmodified and modified antibody-AuNP conjugates incubated for
different time.
Catalytic reduction of para-nitrophenol to aminophenol by sodium borohydride on a
AuNP surface69 was employed to validate the time-dependent formation of a hard protein corona
and formation of the antibody-AuNP conjugate. This reduction occurs on the exposed surface of
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AuNPs; hence we hypothesized that when the AuNP surface is fully saturated with antibodies,
the reduction reaction will be inhibited. To test our hypothesis, purified acrylic acid NHS
modified and unmodified antibodies synthesized at different time points were used to undertake
this reduction reaction. Acrylic acid NHS modified antibody-AuNP conjugates synthesized at 1h,
3h and 6h catalyzed the reduction reaction, whereas the unmodified antibody-nanoparticle
conjugates did not (Figure 20). The requirement of long incubation time for acrylic acid-NHS
modified antibodies to adsorb onto gold demonstrates the importance of free amines in
adsorption of proteins onto AuNPs.
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Figure 20. Kinetics of catalytic activity of acrylic acid NHS-modified and unmodified antibodyAuNP conjugates. Reduction of para-nitrophenol to aminophenol by AuNP was evaluated to
determine the time required for full saturation of AuNP surface by acrylic acid NHS-modified
antibodies.
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In summary, we have demonstrated that the presence of free thiols or amines on proteins
is essential for robust and fast adsorption of proteins onto a AuNP.
Effect of pH on the Synthesis of AuNP-Antibody Conjugates
Antibody-AuNP conjugates were formed by allowing 24h for protein adsorption, and
three factors were considered in evaluating the formation and stability of antibody-AuNP
conjugates at different pH: (1) the surface plasmon resonance of AuNPs, (2) the monolayer
thickness of antibodies on AuNP, and (3) the zeta potential of antibody-AuNP conjugate. UVVisible spectrophotometry, dynamic light scattering (DLS), and nanoparticle tracking analysis
were used to monitor and measure antibody-AuNP stability and protein monolayer thickness in
solution.
UV-visible spectrophotometry has been extensively utilized to monitor nanoparticle size,
stability, and adsorption to other molecules such as proteins due to its ability to measure the
surface plasmon resonance of nanoparticles. A significant red shift and the broadening of the
UV-visible spectra (Figure 21) at pH less than 7.5 for the unmodified antibody-AuNP
conjugates show the presence of aggregates. Electrostatic bridging of antibodies to AuNPs at
lower pH has been determined to be the mechanism by which these aggregates are formed (see
Chapter II). From this observation, we hypothesized that chemical modification of lysine
residues of antibodies to remove some of the positive charges should allow the synthesis of
antibody-AuNP conjugates at lower pH.
NHS and DSP chemically modified antibodies formed a highly stable conjugate with
AuNP. A 3-5 nm red shift in extinction maximum of the AuNPs (Figure 10) and a monolayer
thickness of 8-18 nm (Figure 22) confirms the formation of a stable antibody AuNP conjugate at
pH 6, 6.5, and 7.5 for the modified antibodies. A decrease in the zeta potential of AuNP from -45
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± 3 to -18 ± 4 and -28 ± 5 mV for DSP and NHS chemically modified antibody-AuNP
conjugates respectively, also denotes the formation of an antibody corona on AuNP.
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Figure 21. Evaluating antibody-AuNP conjugate stability at different pH. Extinction spectra of
(A) unmodified antibody-AuNP, (B) acrylic acid NHS-modified antibody-AuNP, and (C) DSPmodified antibody-AuNP conjugates at different pH.
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Figure 22. Hydrodynamic diameter of unmodified and modified antibody-AuNP conjugates at
pH 6.5 measured with DLS.
Quantifying Antibody bound Per AuNP
Antibody density is an important parameter to determine in order to evaluate the
orientation and number of functional antibodies adsorbed onto the AuNP. Most existing
analytical techniques employed to quantify antibody on AuNPs measures supernatant
concentration after centrifuging where the antibody bound is determined by the difference in the
amount added and the amount in the supernatant. Antibodies quantified by these procedures
deviate slightly from the actual amount adsorbed onto AuNP; hence, it is essential to search for
new alternatives for quantifying the number of antibodies on AuNP. Here, a fluorescence and
inductively coupled plasma optical emission spectroscopic technique was developed (Figure 23)
to quantify antibodies and nanoparticles in solution simultaneously. A highly sensitive, but cost
prohibitive, CBQCA fluorescence assay was used to validate our developed native protein
fluorescence assay.
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Figure 23. Schematic illustration of workflow for quantitation of the number of antibodies per
AuNP using florescence and ICP-OES.
In applying this developed method to quantify adsorbed antibodies, the purified antibody
AuNP conjugates were digested with KCN to dissolve the gold and release adsorbed antibodies
into the solution for fluorescence quantification. The number of antibodies bound to each AuNP
was estimated from a standard antibody fluorescence calibration, whereas the number of AuNP
was extrapolated from a gold standard calibration. Digested AuNPs of equivalent concentration
as the one used in preparing conjugates was used as a diluent in all standard fluorescence
solutions, in an effort to matrix match and to ensure accurate protein quantification. The number
of AuNPs was calculated by dividing the mass of gold obtained from the ICP-OES experiment
by the mass of a 60 nm AuNP. The antibody loading per AuNP as a function of the amount of
antibody added to the AuNP suspension was determined using this newly developed method
(Figure 24). The measured quantity of adsorbed antibody was similar when using the native
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fluorescence of the antibody or the costly CBQCA fluorescence assay. Both methods show that a
monolayer coverage is formed with the addition of ≥ 2 mg of antibody per 100 mL of AuNP.
After validating the analytical methodology, antibody loading on the AuNP was quantified for
both modified and unmodified antibodies at different pHs where stable conjugates could be
synthesized (Figure 24). For the unmodified antibodies, only pH 7.5 was considered since
aggregation occurs below pH 7.5. Unmodified antibodies reached a saturated loading of 274 ± 44
antibodies per AuNP at pH 7.5. At pH 7.5 and 6.5, 137 ± 4 and 131 ± 11 antibodies were found
bound per AuNP, respectively, for the NHS modified antibody conjugates.
DSP modified antibody conjugates recorded 320 ± 14, 410 ± 5, and 621 ± 24 at pH 7.5,
6.5, and 6.0, respectively. From the above data, DSP modified antibody conjugates recorded the
highest number of antibodies per AuNP, followed by the unmodified antibody conjugates with
the NHS modified having the least number of antibodies per AuNP.
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Figure 24. Quantitation of number of antibody/AuNP. (A) Florescence adsorption isotherm of
unmodified antibody on AuNP obtained using native protein florescence and a highly sensitive
CBQCA florescence assay.
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These observations align with the DLS size measurement as the size of the antibody
monolayer thickness follows the same trend (Figure 18 & 22). From our results, we observed an
increase in the number of antibodies per AuNPs as the point of interaction on proteins to AuNP
increased. Thus, acrylic acid NHS-modified antibodies with fewer points of interaction with gold
recorded the least number of antibodies per AuNP. Chemical modification of antibody with DSP
adds free thiols to the antibody, which increases the points of interaction with AuNPs. Increasing
the number of free thiols, therefore, enhances the antibody’s binding affinity which promote the
loading of more antibodies onto AuNP. These accounts explain why more DSP modified
antibodies are adsorbed per AuNP.
Based on a geometrical argument, the total number of antibodies theoretically needed to saturate
a 60 nm AuNP was calculated to determine if the number of antibodies bound per AuNP is
within a monolayer coverage. Using standard antibody dimension (14 × 8.5 × 4) a theoretical
minimum and maximum of 95 and 333 antibodies per AuNP were estimated for a 60 nm AuNP
with a total surface area of 11311 nm2. Both unmodified and NHS modified conjugates recorded
antibodies per AuNP within the theoretical monolayer layer saturation range. However, the
number of antibodies per AuNP for DSP modified antibody conjugates was above the theoretical
maximum for a monolayer saturation signifying overcrowding of antibodies on the AuNP
surface. As discussed above, DSP modified antibodies have approximately 10 free thiols, which
is expected to interact with gold most strongly. Also, there is a possibility of a disulfide bond
forming between two antibodies which can affect antibody loading and antigen binding, however
the consistency in the size of antibody before and after the chemical modification which was
determined as 16 ± 2 nm indicates no disulfide formation.
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Figure 25. Quantitation of number of antibody/AuNP at selected pHs for chemically modified
and unmodified antibodies.
Hydrodynamic diameters measured by DLS may include the hydration shell which tends
to increase the size by a few nanometers. Also, the occurrence of very few large particles may
have a major influence on the average conjugate size measured since DLS is biased towards
measuring larger particles. To confirm, if multilayers of antibodies are present on AuNP,
nanoparticle tracking analysis (NTA) was used to validate conjugate size. From Figure 26 an
antibody layer thickness of 15 ± 3 nm was observed signifying a monolayer coverage. The NTA
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results indicate that, the likelihood of disulfide bonds between antibodies leading to the
formation of multilayers of antibody on AuNP is minimal.
A

B

size (nm)
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Figure 26. NTA size distribution of DSP-modified antibody-AuNP conjugate at (A) pH 6.5 and
(B) pH 6.0.
Steric adjustment of antibodies at the expense of their conformation to allow more
antibody packing have been previously reported.70 The high number of DSP modified antibodies
can be attributed to the over packing of antibodies on AuNP due to the high affinity of these
antibodies for AuNPs. Herein we propose over packing of antibodies through steric adjustment
as the pathway leading to a higher density of DSP modified antibodies on AuNP.
We have previously reported the impact of a solution pH on the number of antibodies on
AuNP. Thus, the number of antibodies per AuNP increases as pH decreases from 8.5 to 7.5 for
mouse anti-HRP. This observation was attributed to the different orientation of antibodies at
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these pHs. Likewise, the number of antibodies per AuNP increased significantly from pH 7.5 to
6.0 for the DSP modified antibodies (Figure 25). The solution pH alters the surface charge of
antibodies which influences its orientation as well as loading on AuNP. At lower pHs, more
positive patches are created on the antibody, which directs its orientation on AuNP since
electrostatic interaction between antibodies and AuNP is the primary force that initiates antibody
adsorption onto AuNP. The increase in the number of antibodies with decreasing pH can
therefore be attributed to antibody orientation facilitating more antibody loading.
Quantitation of Antigen-binding Activity of Conjugates
Antibody-AuNP conjugates can only bind antigen if an intact Fab region of the antibody
is exposed. Determining the antigen-binding activity, therefore, gives insight into the orientation
of antibodies on AuNP. Horseradish peroxidase (HRP) is a metalloenzyme that catalyzes the
oxidation of various organic substrates using hydrogen peroxide. HRP can catalyze the oxidation
of 2,2′-Azinobis-(3-Ethylbenzothiazoline-6-Sulfonic Acid) (ABTS). The reaction product is a
metastable cation with an absorption maximum of 419 nm, while the substrate has a maximum of
342 nm; hence, the reaction product of this enzymatic oxidation can be measured with no
interference from the substrate.71 To this end, mouse anti-HRP antibody, which binds
specifically to HRP, was used in all our studies.
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Wash.

Figure 28. Workflow of HRP enzymatic assay for evaluating the antigen binding affinity of
antibody-AuNP conjugates.
Briefly, MAHRP-AuNP conjugates were saturated with excess HRP for 3 h to allow
efficient binding to antibodies. After purification to remove free HRP in solution, an HRP
enzymatic assay was conducted, and the amount of HRP captured by the conjugates was
estimated from an HRP calibration standard. Previously we have demonstrated that there is no
significant difference between the catalytic activity of HRP bound by antibody and free HRP in
solution.72 Hence, we could determine the number of HRP molecules captured by each antibodyAuNP conjugate from an HRP calibration curve. Also, a measured gold intensity via ICP-OES
for each antibody-AuNP was used for normalization to conjugate concentration for easy
comparison between sample preparations. Figure 27A shows the number of moles of HRP
captured by each antibody-AuNP conjugate. The DSP modified antibody-AuNP conjugate
recorded the highest number of HRP followed by the unmodified antibody-AuNP conjugates. No
HRP was captured by conjugates synthesized using the NHS modified antibodies, although there
was a substantial number of antibodies per nanoparticle from our fluorescence assay. In
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accounting for these observations, the number of HRP captured by each conjugate was correlated
to the number of antibodies per AuNP (Figure 27B). As previously discussed, DSP modified
antibody-AuNP conjugate had the highest antibody loading as well.
Consequently, the high number of antigens bound by DSP modified antibody-AuNP
conjugates compared to the unmodified counterpart can be attributed to the density of antibody
per AuNP. The fraction of antibody on AuNP accessible for antigen-binding was also computed
by multiplying the total number of antibodies per AuNP by two and dividing by the total number
of HRP it captures. This calculation was adopted due to the bivalency of antibodies. The fraction
of accessible antigen-binding sites was 33-39% for conjugates made with DSP modified
antibodies at pH 6.0 and 6.5. Similarly, 34% of the unmodified antibodies adsorbed per AuNP
were available for antigen binding at pH 7.5.
Antibodies on AuNP can have a different orientation, which can impact its loading
density. This result suggests the increase in antigen binding of DSP modified antibody-AuNP
conjugates is a result of high antibody loading per AuNP, which is influenced by the orientation
of these antibodies on AuNP. Moreover, the percentage of antibodies accessible for antigen
binding increased from pH 7.5 to 6.0 for the DSP modified antibodies.
Although free thiol has a high affinity for gold compared to amines, all cysteine residue
in the antibody we used for this experiment are engaged in disulfide bonds and are relatively
inaccessible to solvent. Meanwhile, multiple solvent-accessible lysine residues are present in
immunoglobulin G 2a (IgG2A). Therefore, primary amines of lysine residues are a primary
target for the initial coordination of the antibodies to AuNP. Acroleinating primary amines of
lysine through chemical modification of antibodies with acrylic NHS, inhibit interaction of
primary amines of lysine with AuNP. In other to firmly anchor acrylic acid NHS modified

64

antibodies onto AuNP, the antibody would, therefore, have to unfold to expose functional groups
that can actively interact with the nanoparticles. Antibody unfolding may stimulate the loss of
tertiary structure and may lead to loss of antigen-binding. Herein, we propose antibody unfolding
to be the primary reason why acrylic acid NHS-modified antibody-AuNP conjugate captured no
antigen.
Dissecting the Effect of Antibody on AuNP
It has been previously reported that antibody crowding on the AuNP surface can lead to
a decrease in the percentage of active antibodies. Moreover, the number of proteins loaded onto
nanoparticles have been reported to be dependent on the concentration of added protein. To
investigate the possibility of overcrowding in limiting antigen binding by antibodies, different
amount (1.5, 2, 3, 4 ug) of unmodified mouse anti-HRP antibody was added to a fixed
concentration of AuNP at pH 7.5. The fraction of antibodies available for antigen binding was
deduced at each concentration using an HRP enzymatic assay.
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Figure 29. Evaluating the effect of antibody overcrowding on antigen capture efficiency.
(A) Number of antibodies per AuNP at different antibody incubation concentration. (B) Number
of HRP captured by antibody-AuNP conjugates synthesized at each added antibody
concentration. (C) Fraction of antibody accessible to antigens at each antibody concentration.
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Theoretically, the maximum number of antibodies needed to saturate a 60 nm AuNP
entirely is 333 for a side on close packing. Employing the use of our developed fluorescenceICP-OES assay to determine the number of antibodies adsorb at each added concentration, we
recorded 151 ± 7, 184, 230, 231, and 239 antibodies per AuNP at 0.5, 1.5, 2.5, 3 and 4
respectfully (Figure 29A). The data suggest a monolayer saturation at 2.5

g

g. The HRP

enzymatic assay revealed that 33-44% of antibodies were active, and the activity was
independent of the amount of anti-HRP antibody added (Figure 29C). The independency of the
fraction of active antibodies on the amount of added antibody indicates that the percentage of
antibodies on AuNP available for antigen binding is solely dictated by antibody orientation,
which has been found to be impacted by the pH of the solution for unmodified mouse anti-HRP
antibody.
Conclusion
It is well established that protein adsorption onto AuNP is governed by both electrostatic
and covalent interactions. Initially, we had observed aggregation of AuNPs when incubated with
antibodies at pH less than 7.5. By controlling the surface charge of antibodies through chemical
modification with acrylic acid NHS and reduced DSP, stable conjugates were synthesized at pH
6.0 and 6.5. Also, we have established that the presence of free thiols and primary amines on
protein promote quick adsorption of proteins onto AuNP. These studies demonstrate that primary
amine and free thiol are important functionalities that facilitate the adsorption of proteins on
AuNP. Introduction of free sulfhydryl on antibody enhanced the formation of stable and
functional antibody-AuNP conjugates. Although stable conjugates where formed even at acidic
pH when interaction of amines with AuNP was eliminated, through chemical modification of
antibodies with acrylic acid NHS, the conjugates could capture no antigen. Moreover, we have
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confirmed that solution pH is a significant parameter which controls orientation of antibodies on
AuNP. From our studies we can also conclude that the fraction of accessible Fab of antibodies on
AuNP is solely dependent on antibody orientation and not affected by overcrowding of
antibodies on AuNP, at least within our working concentration.
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CHAPTER IV: CONCLUSIONS AND OUTLOOKS
Research Summary
There is growing concern on the fate of nanoparticles for in-vitro and in-vivo biomedical
application due to the potential of biomolecules altering the physicochemical properties of these
nanoparticles.24,37,39,41,42 In this work, the impact of antibody surface charge on the stability of
AuNPs and the mechanism by which antibodies induces aggregation of AuNPs have been fully
evaluated. A systematic workflow was used to synthesize and titrate AuNPs-antibody conjugates
at different pHs. AuNP aggregates were observed when excess antibodies were incubated with
nanoparticles at pH less than 7.5. However, when a stable conjugate was titrated to a pH less
than 7.5 no aggregates were observed. Also, no aggregation of nanoparticles was detected at
pH<7.5 when the surface charge of antibodies was modulated through chemical modification
using acrylic acid NHS which reacts and form an amide with primary amines of lysine residues.
Protein induced AuNP aggregation was intrinsically irreversible when aggregates were allowed
to stand in buffer for 24 hours, however, upon titrating to higher pH by the addition of NaOH,
the aggregates reversed to a normal conjugate size for the first five hours of incubation.
Meanwhile there was no, or little reversibility of aggregates incubated for 24 hours.
From our findings, we conclude that protein surface charge which is dictated by a
solution pH is an important factor to consider when functionalizing AuNPs surface with proteins.
Electrostatic bridging of antibodies between AuNPs was also determined to be the mechanism by
which antibodies triggers AuNP aggregation, since a fully saturated nanoparticle with no
exposed surface is stable after resuspension in buffer (pH 6-6.5) for 24 hours. Moreover, the
ability to synthesize antibody-nanoparticle conjugates after altering the surface charge of
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antibodies through chemical modification also reaffirms the assertion that electrostatic bridging
of antibodies is the predominant interaction which initiates the aggregation of AuNPs.
The impact of a solutions pH on the orientation of antibodies on AuNPs have been fully
studied in our lab.32 The fraction of accessible antigen binding site of antibodies on AuNP have
been determined to increase as pH of the incubating solution decreases, however aggregation of
AuNPs is observed at pH<7.5. As discussed above, the surface charge of antibodies at these pHs
is solely responsible for triggering aggregation of nanoparticles. Chemical modification of
antibodies through reaction primary amines of lysine residues alters antibody surface charge and
allows synthesis of conjugates at pH<7.5. Here, the adsorption dynamics, kinetics and antigen
binding activity of chemically modified antibody-AuNP conjugates have been investigated. UVvisible spectrophotometry, nanoparticle tracking analysis and dynamic light scattering was
employed to undertake all these studies. Chemical modification of antibodies with acrylic acid
NHS and reduced DSP results in the formation of an amide between primary amines of lysine
residues and carboxylate carbonyl chemical modifiers. Reaction of reduced DSP with antibodies
introduces free thiol onto the antibody which enhances antibody adsorption onto AuNP. The
possibility of interaction between primary amines and AuNP is eliminated when reacted with
acrylic acid NHS.
From our observations we conclude that free thiol and amines are important
functionalities for rapid and efficient adsorption of proteins onto AuNPs.
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Outlooks and Future Direction
Gold-nanoparticle enabled immunoassays are rapid and cost effective, however
applicability is limited due to low sensitivity resulting from ineffective immobilization of
antibodies on AuNP. This works provides insight on the possible mechanism by which
antibodies can trigger AuNP aggregation and how this aggregation can be avoided through
chemical modification of antibodies.
Although the presence of highly active points of interaction on the protein, such as free
thiols, increased the number of antigens captured by antibody-AuNP conjugates which may
enhance the sensitivity of AuNP-enabled immunoassay, the orientation of antibodies on AuNP
was random and pH dependent. A site directed immobilization of the Fc portion of antibody on
AuNP after chemical modification of antibodies will improve orientation and prevent
aggregation thereby improving the sensitivity and utility of antibody functionalized AuNPs for
disease diagnosis.
The possibility of antibody unfolding which may reduce antigen binding activity can also
be investigated by employing the use of circular dichroism and FTIR. This study will help
substantiate the effect of the number of points of interaction on protein unfolding when adsorbed
onto nanoparticles.
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